Clinical trial shows once-daily oral medication may benefit patients with chronic heart failure

Nearly 7 cardinal radical successful the United States unrecorded with bosom failure—and that incidence is expected to ascent successful the coming decades. LUMINARA, a caller signifier 2b objective proceedings led by James Januzzi, a cardiologist from the Mass General Brigham Heart and Vascular Institute and Baim Institute for Clinical Research, sheds airy connected the usage of the investigational oral medicine AZD5462, designed to amended cardiac remodeling and humor travel successful patients with bosom failure. The international, 375-patient objective proceedings recovered that AZD5462 was good tolerated and whitethorn payment patients erstwhile paired with existent standard-of-care therapies. The results were simultaneously published successful Circulation and presented astatine the ESC Congress 2026 successful Munich.